28
Oct
2025

Prestige BioPharma Ltd

Exhibitor at CPHI Frankfurt 2025 stand 9.1F99, Integrated Pharma
About Us

PRESTIGE BIOPHARMA (PBP) is an innovative biopharma company specializing in the development and manufacturing of innovative antibody-based drugs and biosimilars. We are expecting EMA approval for our first biosimilar product, Tuznue, in Sep 2024 and is available for partnership. Our innovative pipelines include a mAb targeting pancreatic cancer in clinical trials, and solid t...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • SG
  • 2018
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 9.1F99, Integrated Pharma

Products Featured at CPHI Frankfurt 2025

  • HD201 - Tuznue (Trastuzumab biosimilar)

    Product HD201 - Tuznue (Trastuzumab biosimilar)

  • HD204 (Bevacizumab biosimilar)

    Product HD204 (Bevacizumab biosimilar)

  • PBP1502 (Adalimumab biosimilar)

    Product PBP1502 (Adalimumab biosimilar)

  • PBP1510 (INN:ULENISTAMAB)

    Product PBP1510 (INN:ULENISTAMAB)

    Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinoma up-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer. It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells an...
  • PBP1510 Ulenistamab

    Product PBP1510 Ulenistamab

  • PBP1710 Anti-CTHRC1

    Product PBP1710 Anti-CTHRC1

  • PAUF Pancreatic Cancer Diagnostic Kit

    Product PAUF Pancreatic Cancer Diagnostic Kit

    Pancreatic Adenocarcinoma Up-regulated Factor- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma (PDAC). With our expertise in biosimilars and novel antibody drugs development and manufacturing, we are strongly positioned to tackle the unaddressed need of pancreatic cancer. Early detection an...
  • PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer

    Product PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer

    Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinomaup-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer.

    It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer ce...